Aeglea BioTherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aeglea BioTherapeutics's estimated annual revenue is currently $3.9M per year.
- Aeglea BioTherapeutics received $12.3M in venture funding in June 2017.
- Aeglea BioTherapeutics's estimated revenue per employee is $108,000
- Aeglea BioTherapeutics's total funding is $56M.
Employee Data
- Aeglea BioTherapeutics has 36 Employees.
- Aeglea BioTherapeutics grew their employee count by -63% last year.
Aeglea BioTherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Corporate Development | Reveal Email/Phone |
2 | VP Investor Relations & Corporate Communications | Reveal Email/Phone |
3 | General Counsel | Reveal Email/Phone |
4 | Director Diagnostics and Marketing | Reveal Email/Phone |
5 | Chief Product Officer | Reveal Email/Phone |
6 | Director, Product Operations | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Senior Procurement Manager | Reveal Email/Phone |
9 | Financial Analyst | Reveal Email/Phone |
Aeglea BioTherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Aeglea BioTherapeutics?
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$56M
Total Funding
36
Number of Employees
$3.9M
Revenue (est)
-63%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aeglea BioTherapeutics News
AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ...
AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced the launch of THINK ARGININE, a disease educati ...
AUSTIN, Texas, Feb. 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company's chief financial office ...
AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the U.S. Food and Drug Admin ...
AUSTIN, Texas, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology ...
Other Companies in Austin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.6M | 36 | -66% | $40M |
#2 | $7.3M | 36 | N/A | N/A |
#3 | $4.2M | 36 | -20% | N/A |
#4 | $7.8M | 36 | 3% | N/A |
#5 | $7.1M | 36 | -3% | N/A |
Aeglea BioTherapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-03-24 | $44.0M | B | Lilly Ventures | Article |
| 2017-06-07 | $12.3M | Undisclosed | JonesTrading Institutional Services LLC | Article |